Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI333 in Neovascular Age-related Macular Degeneration
NCT05639530Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI333 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Safety and tolerance indicators at 24 weeks. Started Feb 2023; status: completed.
02
Drugs
IBI333
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05639530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639530.